Navigation Links
Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board

- Internationally Recognized Oncologists Will Offer Strategic Guidance on

Picoplatin Clinical Development -

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the appointment of four additional members to its Clinical Advisory Board to help guide the Company's expanding clinical development strategy for picoplatin. They include Howard A. Burris, III, M.D., of The Sarah Cannon Research Institute in Nashville; E. David Crawford, M.D., of the University of Colorado Comprehensive Cancer Center; Robert F. Ozols, M.D., Ph.D., of the Fox Chase Cancer Center in Philadelphia; and Everett E. Vokes, M.D., of the University of Chicago Pritzker School of Medicine.

These esteemed physicians will add to the already broad expertise of the Company's Clinical Advisory Board and bring an understanding of a wide variety of tumor types, including prostate, breast, ovarian, head and neck and lung cancers, to inform the development of picoplatin. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to address multiple indications, combinations and formulations.

"These renowned physicians are experts in several different indications and will provide strategic input into our clinical development program for picoplatin, which is being developed as a platform product with broad applicability across multiple solid tumor types," said Robert De Jager, M.D., chief medical officer of Poniard.

The new Clinical Advisory Board members join existing members Paul J. Bunn, Jr., M.D., of the University of Colorado Comprehensive Cancer Center; Alan B. Glassberg, former associate director of clinical care and former director of general oncology at the University of California, San Francisco Comprehensive Cancer Center; Richard Goldberg, M.D., of the Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill; and Eric J. Small, M.D., of the University of California, San Francisco.

New Clinical Advisory Board Members

-- Howard A. (Skip) Burris, III, M.D., is chief medical officer and

director of drug development at The Sarah Cannon Research Institute in

Nashville, where he is also an associate with Tennessee Oncology, PLLC.

Dr. Burris' research interests focus on developing investigational

agents and evaluating these compounds in Phase 1 and 2 clinical trials.

He has published papers on taxanes and topoisomerase I inhibitors. He

currently serves on the American Society of Clinical Oncology (ASCO)

Board of Directors and is a member of ASCO's Ethics Committee. He

received his medical degree from the University of South Alabama and

completed his residency and fellowship in hematology/oncology at Brooke

Army Medical Center in San Antonio. While there, he served as director

of clinical research at the Institute for Drug Development of The

Cancer Therapy and Research Center and was an associate professor at

The University of Texas Health Science Center.

-- E. David Crawford, M.D., is the E. David Crawford distinguished

professor of surgery, urology and radiation oncology, and head of the

Section of Urologic Oncology at the University of Colorado Health

Sciences Center in Denver. He also serves as the senior associate

director of the University of Colorado Comprehensive Cancer Center in

Denver. Dr. Crawford, the recipient of nearly 70 research grants, has

conducted research in the treatment of advanced bladder cancer,

metastatic adenocarcinoma of the prostate, hormone refractory prostate

cancer, and other areas of urological infections and malignancies. He

has authored or co-authored more than 450 articles published in

peer-reviewed journals and has published five textbooks and authored

more than 50 book chapters. He is an editorial reviewer or consultant

for many publications, including Urology, Journal of Urology, The New

England Journal of Medicine, Cancer and the Journal of Clinical

Oncology. Dr. Crawford is a member of the American Urological

Association (AUA), for which he was a member of the Prostate Cancer

Clinical Trials Subcommittee. He currently serves on the board of

governors, the GU committee, and the scientific advisory board of the

Southwest Oncology Group and chairs the National Prostate Cancer

Education Council. He received his medical degree from the University

of Cincinnati and completed an internship and residency in urology at

the Good Samaritan Hospital in Cincinnati. He completed a genitourinary

cancer fellowship at the University of California Medical Center in Los


-- Robert F. Ozols, M.D., Ph.D., is senior vice president of Fox Chase

Cancer Center in Philadelphia, where he oversees all of the Center's

patient care, clinical research and medical science laboratory

research. Internationally recognized for his expertise in ovarian

cancer, Dr. Ozols' research focuses on how cancer cells develop

resistance to anticancer drugs and on developing new chemotherapy

regimens for ovarian cancer. He previously served on the Oncologic

Drugs Advisory Committee (ODAC) of the Food and Drug Administration. He

is a former vice president of the International Gynecologic Cancer

Society and served on the Board of Directors of the American Society of

Clinical Oncology and the American Association of Cancer Institutes. He

is past chair of ASCO's Cancer Research Committee and of the Cancer

Communications Committee. He is the author of many scientific

publications and has served on the editorial boards of the

International Journal of Gynecologic Cancer, International Journal of

Oncology, Cancer Research, Cancer Investigation, Journal of

Experimental Therapeutics and Oncology and Clinical Cancer Research. He

earned his bachelor's degree in chemistry, Ph.D. and M.D. from the

University of Rochester. He completed his medical training at

Dartmouth-Hitchcock Medical Center and a medical oncology fellowship at

the National Cancer Institute.

-- Everett E. Vokes, M.D., is the John E. Ultmann Professor of Medicine

and Radiation and Cellular Oncology at the University of Chicago

Pritzker School of Medicine; director of the Section of

Hematology/Oncology; vice chairman for clinical research in the

Department of Medicine; director of the head and neck oncology program;

and deputy director of the University of Chicago Cancer Research

Center. He serves as chair of the Cancer and Leukemia Group B,

Respiratory Core Committee. He is the recipient of numerous research

grants and has authored more than 300 publications in peer-reviewed

journals. He received his medical degree from the University of Bonn

Medical School in West Germany and completed his residency at

Ravenswood Hospital in Chicago and at the University of Southern

California in Los Angeles. He completed a fellowship in

hematology/oncology at the University of Chicago.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Announces Upcoming Conference Participation
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
6. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
10. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
11. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group announced ... clinics in the cities of Arica and Iquique in northern Chile. The facilities are part ... offer the most advanced protocols and techniques in stem cell medicine to patients from around ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
(Date:11/30/2015)...  Culprits beware, a University at Albany research ... is taking crime scene fingerprint identification to a ... -->   --> Photo ... --> Halámek and his team ... concept for identifying whether a culprit is male ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):